HIV-dependent depletion of influenza-specific memory B cells impacts B cell responsiveness to seasonal influenza immunisation

Scientific Reports

Volumn 6, Issue 1, 2016, Pages

  Wheatley, Adam K ^a   Kristensen, Anne B ^a   Lay, William N ^a   Kent, Stephen J ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; VIRUS ANTIBODY;

ADULT; B LYMPHOCYTE; BLOOD; CASE CONTROL STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; INFLUENZA; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); LYMPHOCYTE COUNT; SEASON; VACCINATION; VIROLOGY;

ADULT; ANTIBODIES, VIRAL; B-LYMPHOCYTES; CASE-CONTROL STUDIES; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC MEMORY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; LYMPHOCYTE COUNT; SEASONS; VACCINATION;

EID: 85010899527     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep26478     Document Type: Article

References (61)

1. Moir, S. & Fauci, A. S. Insights into B cells and HIV-specific B-cell responses in HIV-infected individuals. Immunol. Rev. 254, 207–224 (2013).
2. Buckner, C. M. et al. Characterization of plasmablasts in the blood of HIV-infected viremic individuals: evidence for nonspecific immune activation. J. Virol. 87, 5800–5811 (2013).
3. Titanji, K. et al. Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions. AIDS. 19, 1947–1955 (2005).
4. Moir, S. et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J. Exp. Med. 205, 1797–1805 (2008).
5. Kardava, L. et al. Attenuation of HIV-associated human B cell exhaustion by siRNA downregulation of inhibitory receptors. J. Clin. Invest. 121, 2614–2624 (2011).
6. Moir, S. et al. HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc. Natl. Acad. Sci. USA 98, 10362–10367 (2001).
7. Sciaranghella, G., Tong, N., Mahan, A. E., Suscovich, T. J. & Alter, G. Decoupling activation and exhaustion of B cells in spontaneous controllers of HIV infection. AIDS. 27, 175–180 (2013).
8. Lane, H. C. et al. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 309, 453–458 (1983).
9. De Milito, A., Morch, C., Sonnerborg, A. & Chiodi, F. Loss of memory (CD27) B lymphocytes in HIV-1 infection. AIDS. 15, 957–964 (2001).
10. Titanji, K. et al. Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood. 108, 1580–1587 (2006).
11. Chong, Y. et al. Selective CD27+ (memory) B cell reduction and characteristic B cell alteration in drug-naive and HAART-treated HIV type 1-infected patients. AIDS. Res. Hum. Retroviruses. 20, 219–226 (2004).
12. Malaspina, A. et al. Compromised B cell responses to influenza vaccination in HIV-infected individuals. J. Infect. Dis. 191, 1442–1450 (2005).
13. Mena, G., García-Basteiro, A. L. & Bayas, J. M. Hepatitis B and A vaccination in HIV-infected adults: A review. Hum. Vaccin. Immunother. 11, 2582–2598 (2015).
14. Nunes, M. C. & Madhi, S. A. Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals. Hum. Vaccin. Immunother. 8, 161–173 (2012).
15. Pensieroso, S. et al. Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children. Proc. Natl. Acad. Sci. USA 106, 7939–7944 (2009).
16. Moir, S. et al. B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood. 116, 5571–5579 (2010).
17. Montoya, C. J. et al. Abnormal humoral immune response to influenza vaccination in pediatric type-1 human immunodeficiency virus infected patients receiving highly active antiretroviral therapy. Mem. Inst. Oswaldo. Cruz. 102(4), 501–508 (2007).
18. Resino, S. et al. Immunity in HIV-1-infected adults with a previous state of moderate-severe immune-suppression and more than 500 CD4+ T Cell after highly active antiretroviral therapy. J. Clin. Immunol. 24, 379–388 (2004).
19. Sheth, A. N., Althoff, K. N. & Brooks, J. T. Influenza susceptibility, severity and shedding in HIV-infected adults: a review of the literature. Clin. Infect. Dis. 52, 219–227 (2011).
20. Tasker, S. A., Treanor, J. J., Paxton, W. B. & Wallace, M. R. Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 131, 430–433 (1999).
21. Seo, Y. B. et al. Safety and immunogenicity of influenza vaccine among HIV-infected adults: Conventional vaccine vs. intradermal vaccine. Hum. Vaccin. Immunother. 12(2), 478–84 (2015).
22. Curtis, D., Ning, M. F., Armon, C., Li, S. & Weinberg, A. Safety, immunogenicity and shedding of LAIV4 in HIV-infected and uninfected children. Vaccine. 33, 4790–4797 (2015).
23. Ho, J. et al. Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individuals. AIDS. 25, 295–302 (2011).
24. Madhi, S. A., Kuwanda, L., Venter, M. & Violari, A. Prospective cohort study comparing seasonal and H1N1(2009) pandemic influenza virus illnesses in HIV-infected children during 2009. Pediatr. Infect. Dis. J. 33, 174–176 (2014).
25. Leahy, T. R., Goode, M., Lynam, P., Gavin, P. J. & Butler, K. M. HIV virological suppression influences response to the AS03-adjuvanted monovalent pandemic influenza A H1N1 vaccine in HIV-infected children. Influenza. Other. Respir. Viruses. 8, 360–366 (2014).
26. Vigano, A. et al. Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy. J. Acquir. Immune. Defic. Syndr. 48, 289–296 (2008).
27. Levin, M. J. et al. Shedding of live vaccine virus, comparative safety and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine. 26, 4210–4217 (2008).
28. Chadwick, E. G. et al. Serologic response to standard inactivated influenza vaccine in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 13, 206–211 (1994).
29. Kohler, I. et al. The impact of vaccination on the breadth and magnitude of the antibody response to influenza A viruses in HIV-infected individuals. AIDS. 29, 1803–1810 (2015).
30. Soonawala, D., Rimmelzwaan, G. F., Gelinck, L. B., Visser, L. G. & Kroon, F. P. Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination. PloS One. 6, e16496 (2011).
31. Kajaste-Rudnitski, A. et al. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. AIDS. 25, 177–183 (2011).
32. Kroon, F. P. et al. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. AIDS. 12, F217–223 (1998).
33. Agrati, C. et al. Cellular and humoral immune responses to pandemic influenza vaccine in healthy and in highly active antiretroviral therapy-treated HIV patients. AIDS. Res. Hum. Retroviruses. 28, 1606–1616 (2012).
34. Whittle, J. R. R. et al. Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages. J. Virol. 88, 4047–4057 (2014).
35. Kristensen, A. B. et al. Antibody responses with Fc-mediated functions after trivalent influenza vaccination of HIV-infected subjects. J. Virol. Accepted manuscript posted online 6 April 2016. doi: 10.1128/JVI.00285-16.
36. Wheatley, A. K. et al. H5N1 vaccine-elicited memory B cells are genetically constrained by the IGHV locus in the recognition of a neutralizing epitope in the hemagglutinin stem. J. Immunol. 195, 602–610 (2015).
37. McVernon, J. et al. Seroprevalence of 2009 pandemic influenza A(H1N1) virus in Australian blood donors, October - December 2009. Euro. Surveill. 15(40), 19678 (2010).
38. Corti, D. et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 333, 850–856 (2011).
39. Dreyfus, C. et al. Highly conserved protective epitopes on influenza B viruses. Science. 337, 1343–1348 (2012).
40. Tedder, T. F., Clement, L. T. & Cooper, M. D. Expression of C3d receptors during human B cell differentiation: immunofluorescence analysis with the HB-5 monoclonal antibody. J. Immunol. 133, 678–683 (1984).
41. Aguilar-Santelises, M., Mellstedt, H. & Jondal, M. Leukemic cells from progressive B-CLL respond strongly to growth stimulation in vitro. Leukemia 8, 1146–1152 (1994).
42. Overton, E. T. et al. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin. Infect. Dis. 41, 1045–1048 (2005).
43. Valdez, H. et al. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group. AIDS. 14, 11–21 (2000).
44. Lao-araya, M., Puthanakit, T., Aurpibul, L., Sirisanthana, T. & Sirisanthana, V. Antibody response to hepatitis B re-vaccination in HIV-infected children with immune recovery on highly active antiretroviral therapy. Vaccine. 25, 5324–5329 (2007).
45. Puthanakit, T., Aurpibul, L., Yoksan, S., Sirisanthana, T. & Sirisanthana, V. Japanese encephalitis vaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Vaccine. 25, 8257–61 (2007).
46. Aurpibul, L., Puthanakit, T., Sirisanthana, T. & Sirisanthana, V. Response to measles, mumps and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Clin. Infect. Dis. 45, 637–642 (2007).
47. Rinaldi, S. et al. Antibody but not memory B-cell responses are tuned-down in vertically HIV-1 infected children and young individuals being vaccinated yearly against influenza. Vaccine. 32, 657–663 (2014).
48. Sasaki, S. et al. Influence of prior influenza vaccination on antibody and B-cell responses. PloS One. 3, e2975 (2008).
49. Andrews, S. F. et al. High preexisting serological antibody levels correlate with diversification of the influenza vaccine response. J. Virol. 89, 3308–3317 (2015).
50. Tuaillon, E. et al. Long-term persistence of memory B cells specific for hepatitis B surface antigen in HIV-1-infected patients. AIDS 21, 2343–2345 (2007).
51. Bedognetti, D. et al. Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin’s lymphoma patients treated with rituximab-containing regimens. J. Immunol. 186, 6044–6055 (2011).
52. Mina, M. J., Metcalf, C. J., de Swart, R. L., Osterhaus, A. D. & Grenfell, B. T. Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. Science 348, 694–699 (2015).
53. Ahmed, R. & Gray, D. Immunological memory and protective immunity: understanding their relation. Science 272, 54–60 (1996).
54. Li, G. M. et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc. Natl. Acad. Sci. USA 109, 9047–9052 (2012).
55. Wrammert, J. et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. The J. Exp. Med. 208, 181–193 (2011).
56. Corti, D. et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest. 120, 1663–1673 (2010).
57. Couch, R. B. et al. Prior infections with seasonal influenza A/H1N1 virus reduced the illness severity and epidemic intensity of pandemic H1N1 influenza in healthy adults. Clin. Infect. Dis. 54, 311–317 (2012).
58. Hancock, K. et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N. Engl. J. Med. 361, 1945–1952 (2009).
59. Kelly, D. et al. Responses to pandemic ASO3-adjuvanted A/California/07/09 H1N1 influenza vaccine in human immunodeficiency virus-infected individuals. BMC Immunol. 13, 49 (2012).
60. Lagler, H. et al. Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals. PloS One. 7, e36773 (2012).
61. Soonawala, D., Rimmelzwaan, G. F., Gelinck, L. B. S., Visser, L. G. & Kroon, F. P. Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination. PloS One. 6, e16496 (2011).